LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis

[1]  Mingyong Han,et al.  Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. , 2011, International journal of oncology.

[2]  Gerhard Christofori,et al.  The angiogenic switch in carcinogenesis. , 2009, Seminars in cancer biology.

[3]  Fu-Tong Liu,et al.  Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response , 2009, The Journal of experimental medicine.

[4]  F. Spinella,et al.  Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. , 2009, Cancer research.

[5]  N. Tinari,et al.  High expression of 90K (Mac‐2 BP) is associated with poor survival in node‐negative breast cancer patients not receiving adjuvant systemic therapies , 2009, International journal of cancer.

[6]  N. Tinari,et al.  Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. , 2006, Glycobiology.

[7]  D. O’Rourke,et al.  Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. , 2004, Molecular biology of the cell.

[8]  Levon M Khachigian,et al.  Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth , 2003, Nature Medicine.

[9]  J. Parsons,et al.  Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.

[10]  Tae-Hee Lee,et al.  Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability* , 2003, The Journal of Biological Chemistry.

[11]  L. Strizzi,et al.  Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival , 2002, The Journal of pathology.

[12]  A. Marchetti,et al.  Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. , 2002, Cancer research.

[13]  A. Bose,et al.  A Phosphatidylinositol 3-Kinase-independent Insulin Signaling Pathway to N-WASP/Arp2/3/F-actin Required for GLUT4 Glucose Transporter Recycling* , 2002, The Journal of Biological Chemistry.

[14]  N. Tinari,et al.  Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. , 2000, Blood.

[15]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[16]  Rosato,et al.  Differential effect on TCR:CD3 stimulation of a 90‐kD glycoprotein (gp90/Mac‐2BP), a member of the scavenger receptor cysteine‐rich domain protein family , 1998, Clinical and experimental immunology.

[17]  R. Timpl,et al.  Mac‐2 binding protein is a cell‐adhesive protein of the extracellular matrix which self‐assembles into ring‐like structures and binds β1 integrins, collagens and fibronectin , 1998, The EMBO journal.

[18]  N. Tinari,et al.  Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies. , 1997, Biochemical and biophysical research communications.

[19]  G. Neufeld,et al.  Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor (*) , 1996, The Journal of Biological Chemistry.

[20]  S. Barondes,et al.  Galectins. Structure and function of a large family of animal lectins. , 1994, The Journal of biological chemistry.

[21]  A. Ullrich,et al.  The secreted tumor-associated antigen 90K is a potent immune stimulator. , 1994, The Journal of biological chemistry.

[22]  P. Sismondi,et al.  Prognostic value of a novel circulating serum 90K antigen in breast cancer. , 1994, British Journal of Cancer.

[23]  S. Goldman,et al.  The effect of epidermal growth factor on growth and differentiation of mouse preimplantation embryos in vitro. , 1993, Human reproduction.

[24]  E. Taylor,et al.  Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. , 1993, The Journal of biological chemistry.

[25]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[26]  N. Weidner,et al.  Localization of nuclear matrix proteins (NMPs) in multiple tissue types with NM-200.4 (an antibody strongly reactive with NMPs found in breast carcinoma). , 1991, The American journal of pathology.

[27]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[28]  S. Iacobelli,et al.  Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. , 1986, Cancer research.

[29]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[30]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[31]  S. Iacobelli,et al.  Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactoside‐binding soluble 3 binding protein (LGALS3BP) , 2010, International journal of cancer.

[32]  W. Klohs,et al.  Antiangiogenic agents. , 1999, Current opinion in biotechnology.